GlassScriptPhysician profile
Elizabeth W Mitchell
NPI 1962430074
$5,390.11
in general payments reported to CMS, 2019-2025
29 companies · $844 in 2025
The $844 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $287 · 2021: $531 · 2022: $1,003 · 2023: $978 · 2024: $1,192 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,014.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $1,051.08 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $816.73 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $558.88 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Johnson & Johnson Surgical Vision, INC. | $468.53 | 2019-2025 | Catalys System, Tecnis Simplicity, Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $427.02 | 2019-2021 | |
| Allergan, INC. | $297.45 | 2019-2022 | |
| Glaukos Corporation | $269.30 | 2020-2023 | Kxl1b-Ce-Marked Kxlsystem, Kxl System (Not Refurbished) |
| Ocular Therapeutix, INC. | $202.25 | 2020-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $184.39 | 2020-2023 | |
| Mallinckrodt Hospital Products INC. | $134.39 | 2020-2025 | Acthar |
| Dompe US, INC. | $119.91 | 2024 | Oxervate |
| Biotissue Holdings INC. | $105.01 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $101.44 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $90.50 | 2024-2025 | Xdemvy |
| Rayner Intraocular Lenses Limited | $54.96 | 2024 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $54.88 | 2024-2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $54.43 | 2019-2020 | |
| Sight Sciences, INC. | $47.36 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $46.66 | 2020-2023 | Rocklatan |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Kala Pharmaceuticals, INC. | $37.13 | 2019-2021 | |
| Shire North American Group INC | $36.22 | 2019 | |
| Ani Pharmaceuticals, INC. | $34.42 | 2023 | Purified Cortrophin Gel |
| Harrow Eye, LLC | $31.87 | 2025 | Vevye |
| Amgen INC. | $29.49 | 2025 | Tepezza |
| Rxsight INC | $28.41 | 2021-2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Eyevance Pharmaceuticals LLC | $26.92 | 2022 | |
| Beaver-Visitec International, INC. | $21.22 | 2021 | |
| Eyepoint US, INC. | $20.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.